Known hypersensitivity to the active ingredient. Not to be used in conjunction with atropine. Not to be used with general anaesthesia because of a possible hypotensive effect. Antagonistic to the effects of prostaglandin F2-alpha and oxytocin.

Planipart is a beta-adrenergic stimulant and is therefore antagonised by beta-adrenergic blocking agents. In order to prevent additive effects, the product should not be given with other sympathomimetics or vasodilators. In case of accidental overdose, a beta-blocker such as propranolol may be used as an antidote.

Cattle must not be slaughtered for human consumption during treatment or until 14 days from the last treatment. Milk for human consumption must not be taken during treatment or within 60 hours from the last treatment.

When using do not eat, drink or smoke. After use, wash any contaminated skin immediately with soap and clean water. This product contains clenbuterol, a beta-agonist. Accidental self-injection may produce tachycardia and tremor. These effects may be reversed by the use of a non-selective beta-blocker. If accidental self-injection occurs seek medical advice immediately, avoiding driving if possible.

Clenbuterol decreases the tonus of the uterine muscles. Pregnant women should avoid any risk of exposure to Planipart and should not administer the product.

Unused product and containers should be disposed of in accordance with national requirements.

For animal treatment only.